Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8075300 | 0.89 | HSD11B1 (0.37) | KEAP1NFE2L2HSD11B1RORCLMNA | |
| SCHEMBL8500779 | 0.82 | KEAP1 (0.39) | KEAP1NFE2L2HSD11B1RORCLMNA | |
| SCHEMBL8501049 | 0.77 | HSD11B1 (0.35) | KEAP1NFE2L2HSD11B1LMNANPSR1 | |
| SCHEMBL2581276 | 0.76 | KEAP1 (0.44) | KEAP1NFE2L2HSD11B1RORCLMNA | |
| SCHEMBL5928160 | 0.75 | KEAP1 (0.38) | KEAP1NFE2L2HSD11B1RORCLMNA | |
| SCHEMBL7587276 | 0.74 | KMT2A (0.37) | KEAP1NFE2L2RORCNPSR1ALDH1A1 | |
| SCHEMBL5691126 | 0.74 | KEAP1 (0.39) | KEAP1NFE2L2HSD11B1RORCLMNA | |
| SCHEMBL6387295 | 0.73 | RORC (0.33) | RORCLMNAALDH1A1HPGDPOLB | |
| SCHEMBL6388747 | 0.73 | KEAP1 (0.33) | KEAP1NFE2L2RORCLMNAMAPT | |
| SCHEMBL4974737 | 0.73 | SPPL2A (0.40) | LMNAMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040260095-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 2004-12-23 | — | — | US | disclosed |
| US-6730669-B2 | PROPHYLACTICALLY PREVENTING RETROVIRAL INFECTION OR THE SPREAD OF A RETROVIRUS, AND TREATMENT OF A RETROVIRAL INFECTION | G. D. SEARLE & CO. | 2004-05-04 | — | — | US | disclosed |
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | G. D. SEARLE & CO. | 2003-11-20 | — | — | US | disclosed |
| EP-0813542-B1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6310080-B1 | TREATING RETROVIRAL INFECTIONS SUCH AS AIDS | G. D. SEARLE & CO. | 2001-10-30 | — | — | US | disclosed |
| US-6140505-A | REACTING A BENZO FUSED HETEROCYCLIC COMPOUND WITH AN SO3 COMPLEX IN THE PRESENCE OF A WATER IMMISCIBLE, NON-REACTIVE SOLVENT, AT A TEMPERATURE OF FROM ABOUT 0 TO ABOUT 75 DEGREES C., COOLING AND THEN ADDING OXALYL HALIDE. | G. D. SEARLE & CO. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5968970-A | TREATMENT OF HIV | G. D. SEARLE & COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
| US-5965601-A | NOVEL COMPOUNDS FOR INHIBITING REPLICATION OF A RETROVIRUS; TREATING HIV | G. D. SEARLE & CO. (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216435-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | KEAP1 4428/4885NFE2L2 4412/4885HSD11B1 3480/4885 |
| US-20040260095-A1 | Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors | DNPEP, PREP, ANPEP | KEAP1 4428/4885NFE2L2 4412/4885HSD11B1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.